Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

878119C

Avanti

C16 Lyso PAF

Avanti Research™ - A Croda Brand 878119C

Sinónimos:

1-O-hexadecyl-2-hydroxy-sn-glycero-3-phosphocholine

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C24H52NO6P
Número de CAS:
52691-62-0
Peso molecular:
481.65
UNSPSC Code:
12352211
NACRES:
NA.25

form

liquid

packaging

pkg of 1 × 1 mL (878119C-5mg)

manufacturer/tradename

Avanti Research™ - A Croda Brand 878119C

concentration

5 mg/mL (878119C-5mg)

lipid type

bioactive lipids
phosphoglycerides

shipped in

dry ice

storage temp.

−20°C

SMILES string

O[C@](COP([O-])(OCC[N+](C)(C)C)=O)([H])COCCCCCCCCCCCCCCCC

InChI

1S/C24H52NO6P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-29-22-24(26)23-31-32(27,28)30-21-19-25(2,3)4/h24,26H,5-23H2,1-4H3/t24-/m1/s1

InChI key

VLBPIWYTPAXCFJ-XMMPIXPASA-N

General description

1-O-hexadecyl-sn-glycero-3-phosphocholine (C16:0 lyso PAF) is a precursor and metabolite of 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine (C16:0 PAF). Increased levels of C16:0 lyso-PAF has been observed in temporal cortex of Alzheimer disease patients.[1] Lyso-PAF is synthesized from 1-O-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine (1-alkyl-phosphatidylcholine) by the enzyme phospholipase A2 in the remodeling pathway.[2]

Application

C16 Lyso PAF or 1-O-hexadecyl-sn-glycero-3-phosphocholine has been used as a substrate of lysoplasmalogen (LysoPls)-specific phospholipase D (lysophospholipase D (LysoPLD) in an experimental assay.[3] It has also been used as an authentic standard for generating standard curves for quantification of lipid analytes.[4]

Packaging

5 mL Clear Glass Sealed Ampule (878119C-5mg)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

Hazard Classifications

Acute Tox. 3 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 3 - Carc. 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 1 - STOT SE 3

target_organs

Central nervous system, Liver,Kidney

Storage Class

6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

wgk_germany

WGK 3

flash_point_f

does not flash

flash_point_c

does not flash

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Scott D Ryan et al.
Proceedings of the National Academy of Sciences of the United States of America, 106(49), 20936-20941 (2009-11-21)
Perturbation of lipid second messenger networks is associated with the impairment of synaptic function in Alzheimer disease. Underlying molecular mechanisms are unclear. Here, we used an unbiased lipidomic approach to profile alkylacylglycerophosphocholine second messengers in diseased tissue. We found that
Hideo Shindou et al.
The Journal of biological chemistry, 282(9), 6532-6539 (2006-12-22)
Platelet-activating factor (PAF) is a potent proinflammatory lipid mediator eliciting a variety of cellular functions. Lipid mediators, including PAF are produced from membrane phospholipids by enzymatic cascades. Although a G protein-coupled PAF receptor and degradation enzymes have been cloned and
Saki Yamaura et al.
Clinica chimica acta; international journal of clinical chemistry, 481, 184-188 (2018-03-20)
Measurement of lipoprotein-associated phospholipase A2 (Lp-PLA2) can be used as an adjunct to traditional cardiovascular risk factors for identifying individuals at higher risk of cardiovascular events. This can be performed by quantification of the protein concentration using an ELISA platform
Kelsey B Law et al.
Autophagy, 13(5), 868-884 (2017-05-20)
Peroxisome biogenesis disorders (PBDs) are metabolic disorders caused by the loss of peroxisomes. The majority of PBDs result from mutation in one of 3 genes that encode for the peroxisomal AAA ATPase complex (AAA-complex) required for cycling PEX5 for peroxisomal
Michael A Kennedy et al.
PLoS genetics, 10(1), e1004010-e1004010 (2014-01-28)
Unbiased lipidomic approaches have identified impairments in glycerophosphocholine second messenger metabolism in patients with Alzheimer's disease. Specifically, we have shown that amyloid-β42 signals the intraneuronal accumulation of PC(O-16:0/2:0) which is associated with neurotoxicity. Similar to neuronal cells, intracellular accumulation of

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico